At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Tamoxifen +1 moredrug
Likely dose
Tamoxifen 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
In Brief
A Phase 2 clinical trial evaluating Tamoxifen and Breast cancer surgery for Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartAug 2012
Primary CompletionNov 2016
TodayJul 2026
First PostedJun 7, 2012
Enrollment StartAug 1, 2012
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.1 years ago
Interventions
Tamoxifendrug
All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
Breast cancer surgeryprocedure
Breast cancer surgery